Related references
Note: Only part of the references are listed.Comparison in the In Vitro Inhibitory Effects of Major Phytocannabinoids and Polycyclic Aromatic Hydrocarbons Contained in Marijuana Smoke on Cytochrome P450 2C9 Activity
Satoshi Yamaori et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Satoshi Yamaori et al.
DRUG METABOLISM AND DISPOSITION (2011)
Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids
Satoshi Yamaori et al.
FORENSIC TOXICOLOGY (2011)
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes
Rongrong Jiang et al.
LIFE SCIENCES (2011)
Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety
Satoshi Yamaori et al.
LIFE SCIENCES (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis
M. P. Lim et al.
CELL DEATH & DISEASE (2011)
Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes
Satoshi Yamaori et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy Depression is a major confounding factor
Dinesh Selvarajah et al.
DIABETES CARE (2010)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy
Mohanraj Rajesh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis
Derick T. Wade et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
R. B. C. Kavia et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
C. Collin et al.
NEUROLOGICAL RESEARCH (2010)
Distinct Effects of Delta 9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing
Paolo Fusar-Poli et al.
ARCHIVES OF GENERAL PSYCHIATRY (2009)
CYP2C19 inhibition: The impact of substrate probe selection on in vitro inhibition profiles
Robert S. Foti et al.
DRUG METABOLISM AND DISPOSITION (2008)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes
Sirimas Sudsakorn et al.
DRUG METABOLISM AND DISPOSITION (2007)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
AW Zuardi et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2006)
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
RS Obach et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
XQ Li et al.
DRUG METABOLISM AND DISPOSITION (2004)
Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes
XX Cai et al.
DRUG METABOLISM AND DISPOSITION (2004)
Pharmacokinetics and pharmacodynamics of cannabinoids
F Grotenhermen
CLINICAL PHARMACOKINETICS (2003)
Cannabidiol: An overview of some pharmacological aspects
R Mechoulam et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes
M Miyazawa et al.
DRUG METABOLISM AND DISPOSITION (2002)
(+)-N-3-benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19
H Suzuki et al.
DRUG METABOLISM AND DISPOSITION (2002)
Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers
AT Harvey et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver
S Kanamitsu et al.
PHARMACEUTICAL RESEARCH (2000)
Share Paper
